Management of inflammatory bowel diseases in Eastern Europe

Postgraduate Medical Journal

Volumn 82, Issue 966, 2006, Pages 270-273

  Lakatos, L ^b   Lakatos, P L ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Csolnoky F Province Hospital   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BALSALAZIDE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; ENEMA; INFLIXIMAB; MESALAZINE; METRONIDAZOLE; OLSALAZINE; SALAZOSULFAPYRIDINE; VISILIZUMAB;

BARIUM ENEMA; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; ENTERITIS; EUROPE; GASTROINTESTINAL ENDOSCOPY; HUMAN; ILEITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; SEROLOGY; ULCERATIVE COLITIS;

EUROPE, EASTERN; GASTROINTESTINAL AGENTS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES;

EID: 33645916053     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2005.043901     Document Type: Review

References (48)

1. Sartor RB, Mayer L. Editorial introduction. Gastroenterology 2004;126:1503.
2. Carter MJ, Lobo AJ, Travis SPI, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53(suppl V):v1-16.
3. Kombluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Commettee. Am J Gastroenterol 2004;99:1371-85.
4. Xu CT, Meng SY, Pan BR. Drug therapy for ulcerative coilitis. World J Gastroenterol 2004;10:2311-17.
5. Lakatos L, Lakatos PL. Is the incidence and prevalence of inflammatory bowel diseases increasing in Eastern Europe? Postgrad Med J, (in press).
6. Nayar M, Rhodes JM. Management of inflammatory bowel disease. Postgrad Med J 2004;80:206-13.
7. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989;24(suppl 170):2-6.
8. Kull K, Salupere R, Uibo R, et al. Antineutrophil cytoplasmic antibodies in Estonian patients with inflammatory bowel disease. Prevalence and diagnostic role. Hepatogastroenterol 1998;45:2132-7.
9. Barta Z, Csipo I, Szabo GG, et al. Seroreactivity against Saccharomyces cerevisiae in patients with Crohn's disease and celiac disease. World J Gastroenterol 2003;10:2308-12.
10. Bartunkova J, Kolarova I, Sediva A, et al. Antineutrophil cytoplasmic antibodies, anti-Saccharomyces cerevisiae antibodies, and specific IgE to food allergens in children with inflammatory bowel diseases. Clin Immunol 2002;102:102-8.
11. Mokrowiecka A, Gasiorowska A, Malecka-Panas E. Assessment of usefulness of anti-Saccharomyces cerevisiae and anti-neutrophil cytoplasmic antibodies in patients with unspecific inflammatory bowel diseases. Pol Merkuriusz Lek 2004;17(suppl 1):22-6.
12. Malickova K, Janatkova I, Fucikova T, et al. Initial experience with detection of Saccharomyces cerevisiae antibodies in patients with primary nonspecific inflammatory bowel disease. Epidemiol Mikrobiol Imunol 2001;50:131-5.
13. Saibeni S, Folli C, de Franchis R, et al. Diagnostic role and clinical correlates of anti-Saccharomyces cervesiae antibodies (ASCA) and anti-neutrophil cytoplasmic antibodies (p-ANCA) in Italian patients with inflammatory bowel diseases. Dig Liver Dis 2003;35:862-8.
14. Basu D, Lopez I, Kulkarni A, et al. Impact of race and ethnicity on inflammatory bowel diseases. Am J Gastroenterol 2005;100:2254-61.
15. Lawrance IC, Murray K, Hall A, et al. A prospective comparative study of ASCA and pANCA in Chinese and Caucasian IBD patients. Am J Gastroenterol 2004;99:2186-94.
16. Lakatos PL, Lakatos L, Szalay F, et al. Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn disease: phenotype-genotype correlations. World J Gastroenterol 2005;11:1489-95.
17. Lakatos L, Pandur T, David G, et al. Association of extraintestinal manifestations of inflammatory bowel disease (IBD) in a province of Western Hungary with disease phenotype: results of a 25-year follow-up study. World J Gastroenterol 2003;9:2300-7.
18. Herfarth H. Laboratory values, endoscopy and new imaging. What is the status of diagnosis? Internist 2002;43:1354-8.
19. Racz I, Nemeth A, Toth E, et al. Capsule endoscopy in small bowel diagnostics. Orv Hetil 2003;144:2159-64.
20. Molnar T, Papos M, Gyulai Cs, et al. Clinical value of Technetium-99m-HMPAO-labeled leukocyte scintigraphy and spiral computed tomography in active Crohn's disease. Am J Gastroenterol 2001;96:1517-21.
21. Itzkowifz SH, Present DH. Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:314-21.
22. Eaden JA, Mayberry JF. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut 2002;51(suppl V):v10-12.
23. Lakatos L, Mester G, Erdelyi Z, et al. Risk factors for ulcerative colitis associated colorectal cancers in a Hungarian cohort of ulcerative colitis patients. Results of a population based study. (In Hungarian). Orv Hetil 2006;147:175-81.
24. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-35.
25. Maratka Z, Nedbal J, Kocianova J, et al. Incidence of colorectal carcinoma in pancolitis: a retrospective study of 959 cases over 40 years. Gut 1985;26:43-9.
26. Stone MA, Mayberry JF, Baker R. Prevalence and management of inflammatory bowel disease: a cross-sectional study from central England. Eur J Gastroenterol Hepatol 2003;15:1275-80.
27. Hanauer SB. Crohn's disease: step up or top down therapy. Best Practice Res 2003;17:131-7.
28. Hanauer SB. Medical therapy for ulcerative colitis 2004. Gastroenterology 2004;126:1582-92.
29. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5.
30. Van Assche G, D'Haens G, Noman M, et al. Randomized double blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003;125:1025-31.
31. Van Assche G, Vermeire S, Rutgeerts P. Medical treatment of inflammatory bowel diseases. Curr Opin Gastroenterol 2005;21:443-7.
32. Molnar T, Szepes Z, Nagy F, et al. Open questions concerning cyclosporine therapy in ulcerative colitis. Gastroenterology 2004;126:1495-6.
33. Actis GC, Lagget M, Rizzetto M, et al. Long-term efficacy of oral microemulsion cyclosporin for refractory ulcerative colitis. Minerva Med 2005;95:65-70.
34. McDonald JW, Feagan BG, Jewell D, et al. Cyclosporine for induction of remission in Crohn's disease. Cochrane Library. Issue 2. Chichester: Wiley, 2005.
35. Zvirbliene A, Kiudelis G, Kupcinskas L. Retrospective analysis of case histories of patients with ulcerative colitis and Crohn's disease. Medicina (Kaunas) 2003;39:745-50.
36. Travis SP. Review article: the management of mild to severe acute ulcerative colitis. Aliment Pharmacol Ther 2004;20(suppl 4):88-92.
37. Guslandi M. Antibiotics for inflammatory bowel disease: do they work? Eur J Gastroenterol Hepatol 2005;17:145-7.
38. Steinhart AH, Feagan BG, Leddin DJ, et al. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomised, controlled trial. Gastroenterology 2002;123:33-40.
39. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease. Cochrane Library. Issue 1. Chichester: Wiley, 2005.
40. Dejaco C, Harrer M, Waldhoer T, et al. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. Aliment Pharmacol Ther 2003;18:1113-20.
41. Lakatos PL, Szalay F, Tulassay Z, et al. Clinical presentation of Crohn's disease: Association between familial disease, smoking, disease phenotype, extraintestinal manifestations and need for surgery. Hepatogastroenterology 2005;52:817-22.
42. Siegel CA, Sands BE. Review article: practical management of inflammatory bowel disease patients taking immunomodulators. Aliment Pharmacol Ther 2005;22:1-16.
43. Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Library. Issue 1. Chichester: Wiley, 2005.
44. Simon L, Salamon A, Nemesanszky E. First experience with infliximab in Crohn's disease. Results from a multicenter study in Hungary. LAM 2004;14:483-7.
45. Sands BE, Anderson FH, Bernsteint CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85.
46. Schwab R, Lakatos PL, Schafer E, et al. Long-term management of resistant, fistulizing Crohn's disease by ongoing 4-weekly infliximab therapy. Z Gastroenterol 2005;43:510.
47. Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, and placebo: a 2-year trial. Gastroenterology 2004;127:723-9.
48. Yamamoto T. Factors affecting recurrence after surgery for Crohn's disease. World J Gastroenterol 2005;11:3971-9.